Cryomass Technologies Stock Performance
| CRYM Stock | USD 0.02 0.0003 1.89% |
On a scale of 0 to 100, Cryomass Technologies holds a performance score of 1. The firm shows a Beta (market volatility) of 1.42, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cryomass Technologies will likely underperform. Please check Cryomass Technologies' downside variance, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Cryomass Technologies' price patterns will revert.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Cryomass Technologies are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, Cryomass Technologies displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 329.8 K | |
| Total Cashflows From Investing Activities | -2.8 M | |
| Free Cash Flow | -5.8 M |
Cryomass |
Cryomass Technologies Relative Risk vs. Return Landscape
If you would invest 2.28 in Cryomass Technologies on September 18, 2024 and sell it today you would lose (0.72) from holding Cryomass Technologies or give up 31.58% of portfolio value over 90 days. Cryomass Technologies is currently generating 0.3188% in daily expected returns and assumes 14.2382% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Cryomass, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cryomass Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cryomass Technologies' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cryomass Technologies, and traders can use it to determine the average amount a Cryomass Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0224
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRYM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.24 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.32 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Cryomass Technologies is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cryomass Technologies by adding it to a well-diversified portfolio.
Cryomass Technologies Fundamentals Growth
Cryomass OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Cryomass Technologies, and Cryomass Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cryomass OTC Stock performance.
| Return On Equity | -1.16 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 42.41 M | |||
| Shares Outstanding | 202.53 M | |||
| Price To Book | 4.44 X | |||
| EBITDA | (7.9 M) | |||
| Cash And Equivalents | 2.19 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 177.08 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.05 X | |||
| Cash Flow From Operations | (5.6 M) | |||
| Earnings Per Share | (0.08) X | |||
| Total Asset | 15.58 M | |||
About Cryomass Technologies Performance
By examining Cryomass Technologies' fundamental ratios, stakeholders can obtain critical insights into Cryomass Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cryomass Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Cryomass Technologies Inc. designs, sells, and commercializes cryo-mechanical system for the handling of harvested hemp, cannabis, and other high-value plants. Cryomass Technologies Inc. was incorporated in 2011 and is headquartered in Denver, Colorado. Cryomass Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Cryomass Technologies performance evaluation
Checking the ongoing alerts about Cryomass Technologies for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cryomass Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cryomass Technologies had very high historical volatility over the last 90 days | |
| Cryomass Technologies has some characteristics of a very speculative penny stock | |
| Cryomass Technologies has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.86 M) with profit before overhead, payroll, taxes, and interest of 37.18 K. | |
| Cryomass Technologies currently holds about 2.19 M in cash with (5.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 26.0% of the company shares are held by company insiders |
- Analyzing Cryomass Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cryomass Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Cryomass Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cryomass Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cryomass Technologies' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Cryomass Technologies' otc stock. These opinions can provide insight into Cryomass Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Cryomass OTC Stock
Cryomass Technologies financial ratios help investors to determine whether Cryomass OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cryomass with respect to the benefits of owning Cryomass Technologies security.